Genomtec S.A.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2017-02-10
Share capital
1,706,463.40 PLN
Activity description

Genomtec is the creator of Genomtec ID, a mobile platform for genetic diagnostics at the point of patient care. The company has developed the GenomtecID Respiratory Panel 5-Plex (RP5-PLEX), which detects viruses and bacteria causing respiratory tract infections and is the only solution of its kind in Europe. Additionally, Genomtec is preparing for technology trials in Asia related to its diagnostic devices.

Registered address
ul. Bierutowska 57-59, 51-317 Wrocław, Poland
Email
Phone
Social media
Electronic delivery address
AE:PL-23003-83556-RDVER-17

Financials

Revenue history (in k)

Filing timeliness

1 of 6 financial statements was filed late (for 2025, 23 days late). All were audited by a statutory auditor.

  • 202507/08/2026
  • 202414/07/2025
  • 202311/07/2024
  • 202229/06/2023
  • 202101/07/2022
  • 202014/07/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Stock quotes

PLN 2.60
-0.03 (-1.14%)
2.552.602.652.6010:0012:0014:0016:00
Open
PLN 2.60
High
PLN 2.66
Low
PLN 2.55
Volume
6.6K
Avg. vol.
35.71K
Market cap
PLN 44.37M
P/E ratio
–
EPS
-PLN 0.67
Shares outstanding
17.06M
52-week
PLN 2.35 – 2.93
Dividend yield
–
Dividend
–
Ex dividend date
–
Exchange
GPW Main Market

Quarterly results

PeriodRevenueEBITNet profit
Q2 2026USD 2.97kUSD -546.19kUSD -559.43k
Q1 2026USD 4.32kUSD -578.61kUSD -593.19k
Q4 2025USD 1.26kUSD -777.75kUSD -804.87k
Q1 2025–––

Results for Q3 2026:Nov 30, 2026

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Division · Scientific research and development1,521 / 1,943
Top 78%
City · Wrocław12,032 / 13,656
Top 88%
Voivodeship · Dolnośląskie21,448 / 23,844
Top 90%
Country · Poland266,571 / 297,266
Top 90%

Results vs industry

Revenue
This companyUSD 4.77kMedianUSD 56.72kAverageUSD 2.72m
Net profit
This companyUSD -2.57mMedianUSD -1.27kAverageUSD -92.87k
Operating costs
This companyUSD 2.42mMedianUSD 66.48kAverageUSD 2.68m
Assets
This companyUSD 2.98mMedianUSD 134.71kAverageUSD 3.04m

Offer

Websites

The site is available in: Polish and English. The site targets these markets: United States.

  • genomtec.comStrona główna - Genomtec
    WordPress 6.9Yoast SEOWPMLApache

Job offers

The company lists many job openings on its own careers page: genomtec.com/o-nas. The first ones are below.

Position
Apprenticeship participants

Authorized Representatives

Leroy Jonathan Huntley age 63 – Management Board Member
Michał Maciej Wachowski age 44 – Management Board Member
Miron Tokarski age 36 – President of the Management Board

Manner of representation

The company is represented by each member of the management board independently.

Supervisory board

Andrzej Taudul age 58 – Supervisory Board Member
Beata Anna Turlejska age 48 – Supervisory Board Member
Paweł Duszek age 39 – Supervisory Board Member
Gualtiero Garlasco – Supervisory Board Member
Trevor Hawkins – Supervisory Board Member

Beneficial owners

Person

Subsidiaries

NameStake
100%
GMT Id S.A.
100%

Capital group

NameOwnership
OPIS GRUPY KAPITAŁOWEJ GENOMTEC S.A.
10%

Bank accounts

Registered as a VAT taxpayer on 2016-12-28.

Debt

No entries in the National Debtors Register (KRZ).

MSiG notices

9 notices recorded in the Court and Commercial Gazette (MSiG).

Publication dateEvent
Feb 26, 2021Transformation registered
Feb 11, 2021Transformation registered
Jan 19, 2021Shareholders' meeting convened
Jan 19, 2021Transformation registered
Oct 15, 2020Transformation registered

Public aid

18 public aid cases recorded, with a total value of $10,391,382.

PurposeGross amount
Aid for research and development projects: experimental development
–
Aid for research and development projects: industrial research
–
Aid for SMEs for innovation support
–

European Funds

3 projects recorded: 2 from FE lists ($119,285) and 1 Commission grant (FTS) ($55,960).

ProjectEU co-financing
Support for preparing an application for an Eurogrant under the EIC Accelerator programme
$14,356
Microrna-based tool for non-invasive early-stage cancer diagnosis
$55,960
Obtaining international patent protection for an invention concerning an innovative method for detecting genetic material in a biological sample and a mobile diagnostic device for implementing it.
$104.9K

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Replicon sp. z o.o.
Amplicon sp. z o.o.
Grupa Psychotronics sp. z o.o.
NLA Systems sp. z o.o.
Spectra-Laser sp. z o.o.
V-Lab sp. z o.o.
Nucleotica sp. z o.o.
Labomatica sp. z o.o.
Kamika sp. z o.o.
Bioaccure sp. z o.o.

Change history

DateEvent
2026-06-11Share capital increase
2025-09-16Share capital increase
2025-03-19Share capital increase
2024-05-16Share capital increase
2023-10-06Share capital increase

FAQ

Last updated: 2026-10-08